| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Dimethyldimyristylammonium bromide is a cationic lipid that does not have specific biological receptors as its primary targets. Its mechanism of action is based on its amphiphilic properties, allowing it to form lipid bilayers and liposomes. As a cationic lipid, it can interact with negatively charged cellular membranes and nucleic acids, facilitating the delivery of therapeutic agents. It has been used in the formation of lipid nanoparticles (LNPs) for mRNA delivery. The compound's primary applications are in drug delivery systems, gene therapy, and as a coating material for capillary electrophoresis.
|
|---|---|
| ln Vitro |
In vitro, dimethyldimyristylammonium bromide is used as a cationic lipid for the formation of lipid nanoparticles (LNPs). Administration of LNPs containing this lipid and encapsulating mRNA encoding a luciferase reporter increases luminescence in HeLa cells. The compound is also used for coating capillary columns in capillary electrophoresis for protein-dye complex analysis. Cellular assays typically evaluate its transfection efficiency, cytotoxicity, or its ability to form liposomes for drug delivery. The compound's cationic nature allows for electrostatic interactions with nucleic acids.
|
| ln Vivo |
In vivo, dimethyldimyristylammonium bromide is used as a component of lipid nanoparticles for drug and gene delivery. LNPs containing this lipid have been shown to increase luminescence in cells when encapsulating mRNA encoding a luciferase reporter. The compound's ability to form stable liposomes makes it suitable for in vivo applications where controlled release and targeted delivery are desired. Specific in vivo data is limited, but its potential as a component of LNPs for mRNA therapeutics is being explored. The compound is classified for research use only.
|
| Enzyme Assay |
In vitro assays for dimethyldimyristylammonium bromide typically evaluate its transfection efficiency or liposome formation. A standard protocol involves preparing lipid nanoparticles (LNPs) by mixing the cationic lipid with other lipids (e.g., phospholipids, cholesterol) in organic solvents, followed by solvent evaporation and hydration. Nucleic acids (e.g., mRNA, siRNA) are encapsulated during LNP formation. Transfection efficiency is assessed by measuring reporter gene expression (e.g., luciferase) in cultured cells (e.g., HeLa cells). Cytotoxicity is evaluated using MTT or similar assays. Liposome size and zeta potential are characterized using dynamic light scattering.
|
| Cell Assay |
Cellular assays for dimethyldimyristylammonium bromide typically evaluate its transfection efficiency or cytotoxicity. A standard protocol involves culturing HeLa or other cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with LNPs containing the compound and encapsulating a reporter mRNA or DNA at varying concentrations. Transfection efficiency is assessed by measuring reporter gene expression (e.g., luciferase activity) after 24-48 hours. Cell viability is assessed using MTT or similar assays. The compound's ability to deliver nucleic acids is compared to other cationic lipids or transfection reagents.
|
| Animal Protocol |
In vivo animal studies for dimethyldimyristylammonium bromide are typically conducted to evaluate its potential as a component of LNPs for drug and gene delivery. A common protocol involves administering LNPs containing the compound to rodents via intravenous injection. Biodistribution and pharmacokinetics of the LNPs are assessed by measuring the encapsulated payload (e.g., mRNA, drug) in tissues and blood. Efficacy studies may use disease models to evaluate therapeutic effects. Toxicity and biocompatibility are evaluated by monitoring body weight, clinical signs, and organ histopathology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for dimethyldimyristylammonium bromide is limited, as it is primarily a research reagent. The compound has a molecular weight of 518.75 g/mol and a molecular formula of C₃₀H₆₄BrN. It is a solid at room temperature and is hygroscopic, requiring storage under inert gas. As a cationic lipid, it is expected to have limited systemic bioavailability when administered orally. When formulated in LNPs, its pharmacokinetics are determined by the LNP properties. Specific ADME data is not available. The compound is stored at room temperature in a cool, dark place.
|
| Toxicity/Toxicokinetics |
Dimethyldimyristylammonium bromide is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound is hygroscopic and should be stored under inert gas, protected from moisture. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
surfactants
Dimethyldimyristylammonium bromide (Dimethylditetradecylammonium bromide, CAS 68105-02-2) is a cationic lipid with the molecular formula C₃₀H₆₄BrN. It is used in the formation of lipid nanoparticles (LNPs) for drug and gene delivery, as a coating material for capillary electrophoresis, and in the crafting of pH-sensitive liposomes. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. |
| Molecular Formula |
C30H64BRN
|
|---|---|
| Molecular Weight |
518.74
|
| Exact Mass |
517.422
|
| CAS # |
68105-02-2
|
| PubChem CID |
3017829
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
167-169ºC
|
| LogP |
7.469
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
32
|
| Complexity |
292
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCC.[Br-]
|
| InChi Key |
IRMGVPILCPGYNQ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C30H64N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31(3,4)30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-30H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
dimethyl-di(tetradecyl)azanium;bromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9277 mL | 9.6387 mL | 19.2775 mL | |
| 5 mM | 0.3855 mL | 1.9277 mL | 3.8555 mL | |
| 10 mM | 0.1928 mL | 0.9639 mL | 1.9277 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
